With a revenue increase of 13.66% in the second quarter 2026, year on year to cumulative value of $6,513 million, Edwards Lifesciences's revenue per employee grew on a trailing twelve months basis to $ 407,031. The productivity of Edwards Lifesciences's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 245 other companies have achieved higher revenue per employee. While Edwards Lifesciences's total ranking has deteriorated compared to the previous quarter from 1332 to 1976. Edwards Lifesciences has 16,000 employees.
Edwards Lifesciences Faces Legal and Financial Challenges Amidst Declining Revenue Productivity In recent developments, Edwards Lifesciences Corporation (NYSE: EW) is prompting attention from investors and analysts alike due to a significant upcoming legal deadline and a notable decline in financial productivity metrics. Investors are being urged to seek legal counsel in relation to a securities class action lawsuit, while the company s financial performance shows signs of deterioration compared to industry peers.On December 13, 2024, the Rosen Law Firm has set a deadline for investors who purchased Edwards Lifesciences securities between February 6, 2024, and July 24, 2024. The firm is advising affected investors to secure counsel as they may be eligible to participate in the lawsuit. This class action raises serious concerns about the company s compliance with securities regulations and the potential financial implications for current and future shareholders. The looming deadline underscores the significance of timely legal action for those who feel impacted by the company’s recent activities during the defined Class Period.
Levi and Korsinsky, LLP, a prominent law firm specializing in securities litigation, has drawn attention to an impending class action lawsuit aimed at Edwards Lifesciences Corporation (NYSE: EW). Investors are being reminded of the lead plaintiff deadline set for December 13, 2024. This legal development comes at a critical time for Edwards, a company well-regarded for its cutting-edge innovations in heart valve therapy and a standout player in the medical devices industry.As of now, Edwards Lifesciences holds approximately 598.1 million shares outstanding, with its stock trading at around $71.55. The class action lawsuit arises amid concerns from investors regarding the company’s financial practices and disclosures, which have led to significant fluctuations in stock value. Participants in the class action may seek to recover losses incurred during periods where stock performance did not align with the company s reported outlook.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
